Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees

Immunologic Research

Volumn 21, Issue 1, 2000, Pages 7-21

  Lockey, T D ^a   Slobod, K S ^a,d   Caver, T E ^a   D'Costa, S ^a   Owens, R J ^a   McClure, H M ^b   Compans, R W ^b   Hurwitz, Julia L ^a,b,c,d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MEMPHIS   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Gp140; HIV vaccine; Neutralization; Non human primate

Indexed keywords

ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT DNA; RECOMBINANT PROTEIN; VACCINIA VACCINE;

ARTICLE; CHIMPANZEE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINIA VIRUS;

EID: 0034051016     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/ir:21:1:7     Document Type: Article

References (63)

1. 1 Murphy BR, Webster RG: Orthomyxoviruses. In Virology. Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds., Lippincott-Raven Publishers, Philadelphia, PA. 1996; p. 1397.
2. 2 Melnick JL: Enteroviruses. polioviruses, coxsackieviruses, echo viruses, and newer enteroviruses. In Virology: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds., Lippincott-Raven Publishers, Philadelphia, PA. 1996; p. 655.
3. 3 Slobod KS, Rencher SD, Farmer A, Smith FS, Hurwitz JL: HIV type 1 envelope sequence diversity in an inner city community. AIDS Res. Hum. Retroviruses 1994;10:873-875.
4. 4 Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway Jr SR, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC, Wong-Staal F: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985;313: 277-284.
5. 5 Rencher SD, Lockey TD, Slobod KS, Hurwitz JL: Drift from the GPGRAF HIV-1 envelope V3 crown sequence in a North American inner city. AIDS Res Hum Retroviruses 1997; 13:527-528.
6. 6 Lockey TD, Hurwitz JL: Size-heterogenous sequences mark hot spots for asparagine, serine, and threonine insertions in HIV type 1 envelope. AIDS Res Hum Retroviruses 1998; 14:717-719.
7. 7 Luciw P: Human immunodeficiency viruses and their replication. In Virology. Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds., Lippincott-Raven Publishers, Philadelphia, PA. 1996; p. 1881.
8. 8 Herman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990;345:622-625.
9. 9 Hu S-L, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
10. 10 Mooij P, van der Kolk M, Bogers WMJM, ten Haaft PJF, Van Der Meide P, Almond N, Stott J, Deschamps M, Labbe D, Momin P, Voss G, Von Hoegen P, Bruck C, Heeney JL: A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 1998;12:F15-F22
11. 11 Stott EJ, Almond N, Kent K, Walker B, Hull R, Rose J, Silvera P, Sangster R, Corcoran T, Lines J, Silvera K, Luciw P, Murphy-Corb M, Momin P, Bruck C: Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen Vir 1998; 79:423-432.
12. 12 Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwanz D, Corse G, AVEG: Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis 1998;177:301-309.
13. 13 Berman PW, Gray AM, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, Francis DP, Gorse G, Schwartz DH: Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis 1997;176:384-397.
14. 14 Burns DPW, Desrosiers RC: Envelope sequence variation, neutralizing antibodies and primate lentivirus persistence. Curr Top Microbiol Immunol 1994;188:185-219.
15. 15 Sharpe SA, Whatmore AM, Hall GA, Grange MP: Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revenant virus. J Gen Virol 1997;78:1923-1927.
16. 16 Van Rompay KK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, Valverde CR, Montefiori DC, Cole KS, Montelaro RC, Miller CJ, Marthas ML: Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998;177:1247-1259.
17. 17 Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, Norrby E: Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 1991;352: 436-438.
18. 18 Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine 1999;5:204-210.
19. 19 Rencher SD, Slobod KS, Dawson D, Lockey TD, Hurwitz JL: Does the key to a successful HIV vaccine lie among the envelope sequences of infected individuals? AIDS Res Hum Retroviruses 1995; 11:1131-1133.
20. 20 Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV: Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:211-219.
21. 21 Slobod KS, Hurwitz JL: Does envelope V3 peptide comprise the principal neutralizing determinant for HIV? Vaccine 1995;13:129.
22. 22 Lockey TD, Slobod KS, Rencher SD, Srinivas RV, Hurwitz JL: Fluctuating diversity in the HTLV-IIIB virus stock: Implications for neutralization and challenge experiments. AIDS Res Hum Retroviruses 1996;12:1297-1299.
23. 23 Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312-8320.
24. 24 Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu J-Y, Emini EA, Koenig S, Zolla-Pazner S: Neutralization of diverse human immunodeficiency virus type 1 variants by anti-V3 human monoclonal antibody. J Virol 1992;66-7538-7542.
25. 25 Gorny MK, Mascola JR, Israel ZR, VanCott TC, Williams C, Balfe P, Hioe C, Brodine S, Burda S, Zolla-Pazner S: A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. Aids Res Hum Retroviruses 1998; 14:213-221.
26. 26 Scott Jr CF, Silver S, Profy AT, Putney SD, Langlois A, Weinhold K, Robinson JE: Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type III-MN strain. Proc Natl Acad Sci USA 1990;87:8597-8601.
27. 27 Moore JP, Trkola A, Korber B, Boots LJ, Kessler II JA, McCutchan FE, Mascola J, Ho DD, Robinson J, Conley AJ: A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunode ficiency virus type 1 has broad reactivity within and outside clade B. J Virol 1995;69: 122-130.
28. 28 Gorny MK, Xu JY, Gianakakos V, Karwowska S, Williams C, Sheppard HW, Hanson CV, Zolla-Pazner S: Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1991;88:3238-3242.
29. 29 D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, Milman G: Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration. AIDS 1994; 8:169-181.
30. 30 Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas III CF, Burton DR, Ho DD: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1999;69:6609-6617.
31. 31 Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun NC, Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-493.
32. 32 Schutten M, McKnight A, Huisman RC, Thali M, McKeating JA, Sodroski J, Goudsmit J, Osterhaus AD: Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS 1993;7:919-923.
33. 33 Posner MR, Cavacini LA, Emes CL, Power J, Byrn R: Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993;6:7-14.
34. 34 Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PWHI, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barhas CF, III: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266: 1024-1027.
35. 35 Conley AJ, Kessler II JA, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, Emini EA: Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994;91:3348-3352.
36. 36 Kowalski M, Potz J, Basiripour L, Dorfman T, Chun Goh W, Terwilliger E, Dayton A, Rosen C, Haseltine W, Sodroski J: Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987;237: 1351-1355.
37. 37 Profy AT, Salinas PA, Eckler LI, Dunlop NM, Nara PL, Putney SD: Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J Immunol 1990;144:4641-4647.
38. 38 Zwart G, Back NK, Ramautarsing C, Valk M, Hoek LVD, Goudsmit J: Frequent and early HIV-1 MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120V3 domain. AIDS Res Hum Retroviruses 1994; 10:245-251.
39. 39 White-Scharf ME, Potts BJ, Smith LM, Sokolowski KA, Rusche JR, Silver S: Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 1993; 192:197-206.
40. 40 Moore JP: Back to primary school. Nature 1995;376:115-115.
41. 41 Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun N-C, Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-493.
42. 42 Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins; Fusogens, antigens, and immunogens. Science 1998;280:1884-1888.
43. 43 Montefiori DC, Moore JP: Magic of the occult? Science 1999;283: 336-337.
44. 44 Kang C-U, Harkharan K, Posner MR, Nara P: Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. J Virol 1993;151:449-457.
45. 45 Rencher SD, Lockey TD, Srinivas RV, Owens RJ, Hurwitz JL: Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Vaccine 1997;15:265-272.
46. 46 Rencher SD Hurwitz JL: Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3 and non-V3-spccific antibodies. J Acquir Immune Defic Syndr 1997;16:69-73.
47. 47 Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD: Inter-and intraclade neutralization of human immunodeficiency virus type 1:Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70:427-444.
48. 48 Robinson HL, Hunt LA, Webster RG: Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993;11:957-960.
49. 49 Letvin NL, Montefiori DC, Yasutomi Y, Perry HC, Davies M-E, Lekutis C, Alroy M, Freed DC, Lord CI, Handt LK, Liu MA, Shiver JW: Potent, protective anti-HIV immune resposnesgeneratedby bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad. Sci USA 1997;94:9378-9383.
50. 50 Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, Verani-Ketter NVS, Erb S, Belshe RB, Wagner LJ, McElrath MJ, Schwartz DH, Fast P, NIAID AIDS VACCINE EVALUATION GROUP: Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retro-viruses 1997;13:1163-1177.
51. 51 Richmond JFL, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, Fenyo EM, Hurwitz JL, Montefiori DC, Robinson HL: Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997;230:265-274.
52. 52 Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL: A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999; 17:1567-1572.
53. 53 Kempe CH, Fulginiti V, Minamitani M, Shinefield H: Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CV1-78). Pediatrics 1968;42:980-985.
54. 54 Benenson AS, Cherry JD, McIntosh K, Connor JD, Alling DW, Nakano J, Rolfe UT, Schanberger JE, Todd WA, DeCastro F, Horvath FL, Bairan A, Phillips IA, Galasso GJ, Mattheis MJ: Basic study and laboratory standardization. J Infect Dis 1977;135:135-144.
55. 55 Connor JD, McIntosh K, Cherry JD, Benenson AS, Alling DW, Rolfe UT, Schanberger JE, Mattheis MJ: Primary subcutaneous vaccination. J Infect Dis 1977;135:167-175.
56. 56 Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Eng J Med 1987;316:673-676.
57. 57 Hallenberger S, Tucker SP, Owens RJ, Bernstein HB, Compans RW: Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. Virology 1993;193:510-514.
58. 58 Ryan KW, Owens RJ, Hurwitz JL: Preparation and use of vaccinia virus vectors for HIV protein expression and immunization. In Immunology methods manual. Lefkovits, I, ed. Academic Press, London, England. 1997; p. 1995.
59. 59 Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rahson A, Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
60. 60 Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM: Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984; 225:840-842.
61. 61 WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994;10:1359
62. 62 Shepherd MJ, Swearington PL: Z-track injections - a step-by-step how-to for an underused IM technique. Am J Nurs 1984;84:746-747.
63. 63 Myers G, Korber B, Wain-Hobson S, Smith RF, Pavlakis GN: Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos, New Mexico. 1993.